Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647009 | 0.80 | PLAU (0.44) | SIGMAR1DRD2DRD3ABCB1ABCG2 | |
| SCHEMBL20909873 | 0.80 | SIGMAR1 (0.58) | SIGMAR1DRD2DRD3TMEM97USP2 | |
| SCHEMBL6649528 | 0.77 | MEN1 (0.48) | SIGMAR1ABCB1ABCG2USP2TAAR1 | |
| SCHEMBL6492509 | 0.77 | PLAU (0.47) | SIGMAR1DRD2DRD3TMEM97USP2 | |
| SCHEMBL6649201 | 0.77 | ESR2 (0.52) | — | |
| SCHEMBL6645986 | 0.76 | SMN1; SMN2 (0.65) | POLB | |
| SCHEMBL22549230 | 0.75 | SIGMAR1 (0.58) | SIGMAR1DRD2DRD3TMEM97USP2 | |
| SCHEMBL6645761 | 0.75 | MAPT (0.50) | DRD2POLBHSD17B10ALDH1A1 | |
| SCHEMBL6645494 | 0.74 | NOD1 (0.39) | ABCB1ABCG2USP2TAAR1PLAU | |
| SCHEMBL6645872 | 0.73 | MELK (0.48) | PLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | SIGMAR1 508/4885DRD2 2035/4885DRD3 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.